Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Dasa Lipovsek

Adnectin Conjugates for Cancer Therapy and Imaging

Bristol-Myers Squibb

Diego Ellerman

Developing A Conjugation-Based Multivalent Ab Format

Genentech

7:00am - 8:00am 60 mins
Breakfast & Registration
8:00am - 8:15am 15 mins
Chairperson’s Remarks
8:15am - 8:45am 30 mins
Next Generation Protein Therapeutics Summit
Adnectin Conjugates for Cancer Therapy and Imaging
  • Dasa Lipovsek - Senior Principal Scientist, Molecular Discovery Technologies, Bristol-Myers Squibb
more

Adnectins are a family of engineered target-binding proteins based on the 10th human fibronectin type III domain. We will describe the properties of Adnectin-drug conjugates and Adnectin-based PET imaging agents, both of which rely on a combination of high affinity for a therapeutically relevant target and fast clearance from tissues free of the target.

8:45am - 9:15am 30 mins
Next Generation Protein Therapeutics Summit
Abdurin-Drug Conjugates: Small Size and Long Half-Life Delivers More Payload to Tumors than Antibodies
  • Kurt Gehlsen - Vice President and Chief Scientific Officer, Research Corporation Technologies, Inc.
more

Abdurins are an antibody-like scaffold platform derived from the CH2 domain of Fc, retain FcRn-binding, leading to a prolonged circulating half-life.  The small size coupled with long half-life facilitates better tissue/tumor penetration and higher target drug concentrations. Recent studies demonstrate that Abdurin-drug conjugates can increased the Therapeutic Index and safely and more effectively deliver toxic payloads in a xenograft model.

9:15am - 9:45am 30 mins
Next Generation Protein Therapeutics Summit
Conjugation and Targeting Ligand Design Strategies for Targeted Polymeric Nanoparticles
  • Manoj Charati - Senior Principal Scientist, Pfizer
more
9:45am - 10:30am 45 mins
Next Generation Protein Therapeutics Summit
Exhibit Hall Opens for Networking Refreshment Break
10:30am - 11:00am 30 mins
Next Generation Protein Therapeutics Summit
Expanding Linkers Beyond Cytotoxins And Higher Drug Payloads: Innovative Linker And Payload Technologies
more

If you are interested in presenting on this topic please contact catherine.marshall@knect365.com

11:00am - 11:30am 30 mins
Next Generation Protein Therapeutics Summit
Preclinical Validation of Site-Specifically Conjugated ADCs With Potent Anthracycline Payloads In Solid & Hematologic Tumors
  • Roger Beerli - CSO, NBE-Therapeutics Ltd.
more

We present a novel ADC format based on the site-specific conjugation of a derivative of the anthracycline PNU-159682 using the transpeptidase Sortase A. The use of a non-cleavable peptide linker provides exquisite stability in vivo, whereas the anthracycline payload endows the ADC with superior potency combined with attractive immune-oncology properties intrinsic to this class of payloads. Validating data obtained in numerous PDX models, as well as in immunocompetent syngeneic models, will be presented.

11:30am - 12:00pm 30 mins
Next Generation Protein Therapeutics Summit
Thought Leaders Discussion: Future Visions - What are the Next Conjugates and How to Overcome Development Challenges?
more
  • Where does the future lie for bioconjugates – What other conjugates are out there?
  • What kind of linker is required?
  • Cleavage sites
  • Safety profile and ensuring long term efficacy
  • Challenges of conjugations and delivering other potent non-antibody molecules e.g. RNAi, modRNA?
  • Cost considerations for complex bioconjugates
  • What disruptive technologies are being developed and applied to overcome development challenges

Panellists made up of speakers from the event

12:00pm - 12:30pm 30 mins
Next Generation Protein Therapeutics Summit
Next Generation ADCs
  • Marie Zhu - CEO of MabPlex US, MabPlex
more

First generation ADCs suffer from heterogeniety issues which can cause efficacy issues along with toxicity. We set out to design a second generation conjugation technology that increased stability and efficacy. This second generation ADC platform allows increased homogeniety without using site directed technologies.

12:30pm - 1:45pm 75 mins
Luncheon in the Exhibit Hall
1:45pm - 2:15pm 30 mins
Next Generation Protein Therapeutics Summit
Developing A Conjugation-Based Multivalent Ab Format
  • Diego Ellerman - Principal Scientific Researcher, Genentech
more

We describe a novel multivalent format based on protein conjugation (TRACS). The building blocks are mAbs and Fabs with good expression yields and stability. A conjugation site that supports high conjugation rates and an efficient process was identified. The spatial arrangement of all the Fabs allows their simultaneous binding with reduced steric hindrance. We provide examples of different TRACS that require concurrent binding of all Fabs for their biological activity.

2:15pm - 2:45pm 30 mins
Next Generation Protein Therapeutics Summit
From Cells to ADCs: A Magnetic Bead-Based Conjugation And High-Throughput Analysis Of ADCs
  • Jelly Netirojjanakul - Senior Scientist, Amgen
more

The use of automated high throughput screening in large molecule discovery research still lags behind that of small molecule discovery.  Here, we developed a magnetic bead-based approach for antibody capture and conjugation, together with an automated platform to complete a bioconjugation optimization. Given LC-MS is a widespread analytical bottleneck, we also established a high-throughput MS platform to accurately detect and rapidly quantitate ADCs with acquisition time of 20 sec/sample, 10-50x improvement over traditional LC-MS methods.

2:45pm - 3:15pm 30 mins
Next Generation Protein Therapeutics Summit
Duorcarmycin Dimer-Based Antibody-Drug Conjugates
  • Thomas Pillow - Senior Scientist, Genentech
more

To enable duocarmycin dimers as payloads for ADCs we investigated various locations on the drug for linker attachment. The use of structure-based drug design facilitated this process and led to highly efficacious conjugates. The impacts of these changes on both efficacy and toxicity will be discussed.

3:15pm - 4:00pm 45 mins
Next Generation Protein Therapeutics Summit
Networking Refreshment Break in the Exhibit Hall
4:00pm - 4:30pm 30 mins
Next Generation Protein Therapeutics Summit
Novel Conjugation Techniques to Improve Selectivity, Yield and Stability
  • Dante Romanini - Senior Scientist, Amgen
more
5:00pm - 5:30pm 30 mins
End of Conference Day One
5:30pm - 7:00pm 90 mins
Cocktail Reception in the Exhibit Hall